东方生物子公司取得两款医疗器械产品注册证书

Core Viewpoint - Dongfang Bio (688298.SH) announced that its subsidiary Hangzhou Danwei Biotechnology Co., Ltd. has obtained registration certificates for two medical device products, enhancing its product offerings in HPV and respiratory virus detection [1] Group 1: Product Development - The two newly registered products are: a nucleic acid detection kit for 14 high-risk types of human papillomavirus (HPV) and a combined nucleic acid detection kit for COVID-19 and influenza A and B viruses [1] - The HPV detection kit expands the company's product range for HPV virus testing in the domestic market [1] - The COVID-19 and influenza detection kit improves the company's portfolio in respiratory virus testing, addressing seasonal respiratory virus infections [1] Group 2: Market Expansion - The registration of these products broadens the company's sales offerings in molecular diagnostic technology, facilitating overall market expansion in China [1]